Cannabis Law Report

JULY 22, 2022

July 21, 2022 08:00 ET | Source: Metrc LLC. July 21, 2022 (GLOBE NEWSWIRE) — Metrc , the most trusted and experienced provider of cannabis regulatory systems in the U.S., July 21, 2022 (GLOBE NEWSWIRE) — Metrc , the most trusted and experienced provider of cannabis regulatory systems in the U.S., LAKELAND, Fla.,

Data 52

Data Programs Access Compliance 52

Cannabis Law Report

AUGUST 16, 2022

16, 2022 (GLOBE NEWSWIRE) — Metrc , the most trusted and experienced provider of cannabis regulatory systems in the U.S., This marks Metrc’s 23 rd government contract to date and sixth so far in 2022. The State plans to begin accepting licensing applications for businesses on September 1, 2022. “We LAKELAND, Fla.,

Seed-To-Sale 52

Seed-To-Sale Supply Chain Data Patients 52

Cannabis Law Report

AUGUST 24, 2022

25 August 2022. New research from the University of Sydney’s Lambert Initiative finds most Australians are still medicating with illicit cannabis, although numbers accessing prescription products have risen dramatically. Here’s what they say – nothing that any cannabis user hasn’t know since the 19080’s !

Medicine 52

Medicine Legalization Chronic Pain Access 52

Cannabis Law Report

SEPTEMBER 7, 2022

Since the legalisation of medical cannabis in the UK in 2018, there is little education surrounding medical cannabis and how it can help a large variety of conditions, should traditional medicine leave patients with an ‘unmet clinical need.’ .

Patients 52

Patients Conditions Treatment Education 52

Cannabis Law Report

JANUARY 3, 2022

According to the amendment to the law on addictive substances and drugs, which came into force on January 1, doctors will now only prescribe medical marijuana to their patients electronically. Almost 200 doctors throughout the Czech Republic are currently prescribing therapeutic cannabis to some of their patients. Source: CTK.

Media 52

Media Chronic Pain Patients Treatment 52

Veriheal

FEBRUARY 9, 2023

The data collected so far by the Turner Institute for Brain and Mental Health at Monash University in Australia suggests that psilocybin not only makes the process more comfortable but, as one participant described, MRIs become “magical.” All imaging and behavioral data will be accessible to the public after the study is complete.

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

Cannabis Law Report

SEPTEMBER 29, 2022

September 27, 2022. On September 22, 2022, Canada’s Minister of Health, Jean-Yves Duclos, and Minister of Mental Health and Addictions and Associate Minister of Health, Carolyn Bennett, announced the overdue legislative review of Canada’s Cannabis Act (Act). By Laura Weinrib , Alexis Levine and Alan Fraser. CANNABIS ACT.

Legislation 59

Legislation Consumption Safety Access 59

Cannabis Law Report

JANUARY 28, 2022

By Maciej Konarowski, President of the Polish Medical Cannabis Patients Association and founder of the Can advocare law firm, and Conor O’Brien, Analyst at Prohibition Partners. 28 January 2022. Demand for medical cannabis from patients in Poland is growing fast, but the government is still failing to ensure adequate supply.

Legislation 52

Legislation Pharmaceutical Agriculture Cultivation 52

Cannabis Law Report

MARCH 8, 2022

DENVER) March 8, 2022 – Simplifya (“Simplifya” or “the Company”), the leading regulatory and operational compliance software platform serving the cannabis industry, announced the launch of its comprehensive suite of compliance solutions in New Mexico, expanding the company’s reach to 24 states. Simplifya Self Audit.

Compliance 98

Compliance Compliance Research and Development Business 98

Cannabis Law Report

APRIL 9, 2022

April 07, 2022 02:00 AM Eastern Daylight Time. The polling data published by Hanway Associates reveals that there is majority support across Europe for legal, government-regulated sales of cannabis products to adults over the age of 18 years. Multiple data sources were used to corroborate the insights for this report.

Legalization 52

Legalization Recreational Data Retail 52

Cannabis Law Report

JUNE 8, 2022

Published: Jun 07, 2022. Experienced healthcare leaders bring decades of experience in global drug commercialization and patient access. SAN JOSE, Calif. , June 7, 2022 /PRNewswire/ — MAPS Public Benefit Corp (MAPS PBC) today announced the appointment of Jeff George and Dan Grossman , Ph.D., He holds a Ph.D.

Therapy 52

Therapy Treatment Access Patients 52

Cannabis Law Report

APRIL 5, 2022

April 05, 2022 (GLOBE NEWSWIRE) — Metrc, the most trusted and experienced provider of cannabis regulatory systems in the U.S., Metrc will help facilitate Mississippi’s medical cannabis program’s data collection and regulatory oversight through its robust track-and-trace platform. Their third new state contract in as many weeks.

Safety 52

Safety Patients Dispensary Compliance 52

Cannabis Law Report

MARCH 23, 2022

LAKELAND, Fla. , March 23, 2022 /PRNewswire/ — Metrc , the most trusted and experienced provider of cannabis regulatory systems in the U.S., This information is accessible to state regulators as well as operators to provide the ultimate transparency and safeguard the health and well-being of South Dakota medical marijuana patients.

Packaging 52

Packaging Programs Collective Concentrates 52

Cannabis Law Report

SEPTEMBER 12, 2022

08, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has completed what it believes to be the largest legal natural psilocybin harvest in Canadian history. To access a complete photo gallery of this historic grow, please click here.

History 52

History Clinical Trials Legalization Research and Development 52

Cannabis Law Report

JULY 24, 2022

The legal framework regarding the use of psychedelics in patients is very pragmatic in Switzerland and unique internationally. Nevertheless, the regulatory hurdles for researchers and patients are still extremely high. A total of 170 patients were treated under these licenses. percent annually to $9.8 billion by 2029. [1]

Research and Development 52

Research and Development Legalization Treatment Patients 52

Veriheal

FEBRUARY 10, 2022

Medical cannabis patient enrollment is on the rise in South Dakota, and what better way to stay on top of things than by introducing a cloud-based platform? cloudPWR and Accela’s cloud-based registry has been publicly accessible since Nov. Patients were given the go-ahead to register for medical cannabis cards on Nov.

Programs 52

Programs Chronic Pain Patients Conditions 52

Illinois News Joint

FEBRUARY 7, 2023

The disparity and availability study begins 12 months of research that will measure accessibility, whether any discrimination exists, whether it impacts entry and participation, and suggest potential remedies for Illinois cannabis regulation. To qualify and receive a medical patient card at a discounted rate, visit here.

Agriculture 79

Agriculture Cannabis Policy Dispensary 79

Cannabis Law Report

MAY 10, 2022

11 May 2022. First academic study of national medicinal cannabis data. Using data from the Therapeutic Goods Administration (TGA) – Australia’s Special Access Scheme B, the researchers found the other two top reasons for prescriptions were pain and sleep disorders. Here’s the Uni of Sydney press release.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JANUARY 4, 2022

By partnering with Gold Leaf in the early stages of their organization’s cultivation journey, we will play an instrumental role in helping their team fulfill their mission of supplying the medical market with the quality cannabis and consistent experiences patients and physicians have come to demand.”. BILLERICA, Mass.,

Extraction 52

Extraction Cultivation Programs Data 52

Veriheal

MARCH 23, 2023

The people of Japan, a country renowned for its sushi cuisine scene, iconic Mount Fuji, and eye-catching cherry blossom trees, may soon have access to legal medicinal marijuana for intractable diseases. Data suggests that the market has inflated from JPY4 billion (USD$3 billion) in 2019 to JPY17 billion (USD$13 billion) in 2022.

Legalization 66

Legalization Marijuana Clinical Trials Seed-To-Sale 66

Cannabis Law Report

MAY 29, 2022

To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision. 12] DEA, Drug Scheduling, [link] (last visited May 13, 2022). [13] 1, 2022), [link]. [14]

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

MAY 18, 2022

Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. The study was completed on March 22, 2022, and involved 1,061 participants, providing a 98% power rating on its results, which is statistically significant. Chief of Regulatory Affairs.

Safety 52

Safety Hemp Research and Development Data 52

Cannabis Law Report

MAY 18, 2022

Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. The study was completed on March 22, 2022, and involved 1,061 participants, providing a 98% power rating on its results, which is statistically significant. Chief of Regulatory Affairs.

Safety 52

Safety Hemp Research and Development Data 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Accessed July 25, 2021. Available at: [link] Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Veriheal

JANUARY 5, 2022

Young and Joyce also question the federal government’s motives, stating, “To be clear, we do not negate the benefit of traditional therapies, but question why the federal government continues to bar access to innovative, proven—and in many cases—safer alternatives.” Young’s Trail of Cannabis Reform.

Legislation 52

Legislation Cannabis Therapy Access 52

Cannabis Law Report

AUGUST 4, 2021

We thus provide comparison with the pre-pandemic period of H1 2019 as an additional data point. At the time of FY 2020 results publication, we estimated that EUR 250m revenues had been lost in FY 2020 due to the impact of COVID-19 lockdowns and travel restrictions and the objective was to recover these revenues by 2022.

Business 105

Business Research and Development Environment Food 105

Cannabis Law Report

NOVEMBER 23, 2021

Five brands in the Tilray portfolio rank in the top five sales brands across adult-use categories based on HiFyre sales data for August through October 2021. Tilray is also committed to growing our Manitoba Harvest business, a pioneer in branded hemp and wellness products, with access to 17,000 stores in North America. About Tilray.

Research and Development 52

Research and Development Cultivation Pharmaceutical Packaging 52

Cannabis Law Report

DECEMBER 21, 2021

The rapid increase in the volume of enterprise data and growing automation of business processes across several end-use industries such as retail, manufacturing, healthcare, and transportation are expected to drive the demand for business software and services over the forecast period. billion in 2020 (Grandview Research). from 2021 to 2028.

Research and Development 52

Research and Development Supply Chain Data Business 52

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 20, 2022

Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines. Medicines and Healthcare products Regulatory Agency’s Innovative Licensing and Access Pathway (“ILAP”), offering the potential to accelerate time to market.

Therapy 52

Therapy Research and Development Business Access 52

Veriheal

OCTOBER 3, 2022

With the growing acceptance and legalization of cannabis, the pharmaceutical industry is taking serious hits, according to a 2022 novel study into the impact of cannabis legalization on pharmaceutical firms. The team that conducted the study looked at stock return and prescription drug sales data for 556 pharmaceutical companies.

Pharmaceutical 104

Pharmaceutical Patients Research and Development Legalization 104

Cannabis Law Report

JANUARY 9, 2022

The state’s medical patients (about 0.5% Regulated sales are scheduled to begin on May 1, 2022. Vermont’s law requires that cannabis tax revenue be “used to fund a grant program to start or expand afterschool and summer learning programs, with a focus on increasing access in underserved areas.”. Sales began in January 2022.

Collective 52

Collective Policy Retail Programs 52

Cannabis Law Report

MAY 6, 2022

As of last month, 3,138 cannabis stores were open across Canada, according to Cannabis Benchmarks, an industry data provider. February 2022 marked my second anniversary as the CEO of Sundial. Survival was the priority, and Sundial was akin to a patient in the ICU. Read more [link]. ALSO SEE DECEMBER 2021. THE LETTER.

Retail 52

Retail Cultivation Business Cannabis 52

The Cannigma

AUGUST 5, 2022

A 2022 study of 22 patients with treatment-resistant depression found a 42% reduction in depressive symptoms with ketamine infusions. Most existing research does not support the use of THC in combating depression and there is very limited data for other cannabinoids.” Depression and psychedelics.

Treatment 138

Treatment Research and Development Therapy Digestion 138

Veriheal

AUGUST 31, 2021

His device not only provides an accessible option for cannabis users who are moving away from smoking but also opens up the opportunity for unique experiences with cannabis in the same way Starbucks revolutionized how people drink coffee. . Camille Elliott. School: Villanova University. Major/Program: Nursing. Benjamin Sanchez.

Research and Development 116

Research and Development Supply Chain Programs Education 116

The Cannigma

JANUARY 13, 2023

The fact that migraine is now ranked as the second leading cause of years lived with disability illustrates the magnitude of the negative impact of the disease to patients and their ability to function normally. A 2019 retrospective review of 316 patients found that medical cannabis improved the experience of 88.3%

Terpenes 132

Terpenes Strains THC Treatment 132